PTC Therapeutics, Inc.

We're committed to a single purpose: Extending life’s moments for patients with rare diseases and their loved ones.

General Information
Company Name
PTC Therapeutics, Inc.
Founded Year
1998
Location (Offices)
Founders / Decision Makers
Peter P. Giannousis - Vice President Technical Operations Mary Frances Harmon - Senior VP, Corporate Relations Mary Ann Johnston - VP, Global Project Lead Kylie O'Keefe - Senior Vice President, Head of Global Commercial and Corporate Strategy Stuart Peltz - Founder and CEO Dhaval Patel - Senior Director & Head, Formulation Development Eric Pauwels - Chief Business Officer
Number of Employees
1150
Industries
Biotechnology, Health Care, Health and Wellness
Funding Stage
Post Ipo Equity
Social Media

PTC Therapeutics, Inc. - Company Profile

PTC Therapeutics, Inc. is a patient-centered biopharmaceutical company with a steadfast commitment to extending life's moments for patients with rare diseases and their loved ones. Founded in 1998, the company operates in the Biotechnology and Health Care industries, maintaining a primary focus on discovering, developing, and commercializing medicines for patients with rare and serious diseases. Notably, PTC recently secured a significant $1.00B Post-IPO Equity investment on 27 October 2022, with funding coming from Blackstone Life Sciences and Blackstone Credit. This substantial investment underscores investor confidence in PTC's mission and potential for impactful advancements in addressing unmet medical needs for patients with rare diseases.

Taxonomy: biopharmaceutical company, rare diseases, patient-centered, medicine development, orphan disorders, ultra-orphan disorders, oncology, anti-infectives

Funding Rounds & Investors of PTC Therapeutics, Inc. (15)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Equity $1.00B 2 Blackstone Life Sciences, Blackstone Credit 27 Oct 2022
Post-IPO Equity $140.95M - 14 May 2020
Post-IPO Debt $150.00M - 14 Aug 2015
Venture Round $4.50M - 15 May 2013
Private Equity Round $60.00M 8
Novo Holdings, investor in PTC Therapeutics, Inc.'s Private Equity Round round Longwood Fund, investor in PTC Therapeutics, Inc.'s Private Equity Round round Vulcan Capital, investor in PTC Therapeutics, Inc.'s Private Equity Round round Delphi Ventures, investor in PTC Therapeutics, Inc.'s Private Equity Round round Adage Capital Management, investor in PTC Therapeutics, Inc.'s Private Equity Round round Credit Suisse, investor in PTC Therapeutics, Inc.'s Private Equity Round round
Jennison Associates, Brookside Capital 		07 Mar 2013

View All 15 Funding Rounds

Latest News of PTC Therapeutics, Inc.

View All

No recent news or press coverage available for PTC Therapeutics, Inc..

Similar Companies to PTC Therapeutics, Inc.

View All
Seelos Therapeutics, Inc. - Similar company to PTC Therapeutics, Inc.
Seelos Therapeutics, Inc. A clinical-stage biopharmaceutical company focused on central nervous system disorders and rare diseases.
PsychoGenics - Similar company to PTC Therapeutics, Inc.
PsychoGenics Discover Your Next Breakthrough
Specialty Pharmacy Nursing Network - Similar company to PTC Therapeutics, Inc.
Specialty Pharmacy Nursing Network We are a network of specialty infusion nurses who provide therapy management for rare, chronic, and orphan disorders.
Versantis - Similar company to PTC Therapeutics, Inc.
Versantis Multiorgan support for rare pediatric and acute liver diseases
Vivet Therapeutics - Similar company to PTC Therapeutics, Inc.
Vivet Therapeutics Vivet Therapeutics develops gene therapy treatments for inherited liver disorders using liver tropic virus.
Circle Decoration Circle Decoration

Want to dive deeper into PTC Therapeutics, Inc.? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now